Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors
Jiao Kong, Ya‐Qiu Long · RSC Medicinal Chemistry · 2022
modulating various signaling pathways, such as the RAS/ERK signaling pathway, and participates in the PD-1/PD-L1 pathway governing immune surveillance. It has been recognized as a breakthrough antitumor therapeutic target. Besides, numerous studies have shown that SHP2 plays an important role in the regulation of inflammatory diseases. However, inhibitors targeting the active site of SHP2 lack drug-likeness due to their low selectivity and poor bioavailability, thus none has advanced to clinical development. Recently, allosteric inhibitors that stabilize the inactive conformation of SHP2 have achieved breakthrough progress, providing the clinical proof for the druggability of SHP2 as an antitumor drug target. This paper reviews the recently reported design and discovery of SHP2 small molecule inhibitors, focused on the structure-activity relationship (SAR) analysis of several representative SHP2 inhibitors, outlining the evolution and therapeutic potential of the small molecule inhibitors targeting SHP2.
Cited by 41 works. doi:10.1039/d1md00386k
Authors
References
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- Crystal Structure of the Tyrosine Phosphatase SHP-2
- Protein Tyrosine Phosphatases in the Human Genome
- The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
- Protein tyrosine phosphatases: from genes, to function, to disease
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor